The goal of this project is to perform experimental clinical testing of an anti-circumsporozoite (CSP) monoclonal antibody, which is derived from protected vaccinees from an RTS,S-AS01 delayed fractional dose Phase 2a clinical trial. 

 

The primary objective is to determine if passive immunization with a single high-avidity anti-NANP (repeat region of CSP) monoclonal antibody can protect an individual against controlled human malaria infection. A secondary objective is to generate evidence to support the development of anti-infection monoclonal antibodies as products.